Stock Ratings / Health Care / TCRT / insiders

KPRX (32) MTVA (47) CURX (37) UPC (33) ⌘ Pro Terminal →

Alaunos Therapeutics Inc. (TCRT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.89 -11.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Alaunos Therapeutics Inc. (TCRT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $7.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TCRT)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TCRT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TCRT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TCRT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TCRT)

✓Walkthrough of TCRT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TCRT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.88%📐 HORIZONTAL RANGE

2026-10-30O $1.84H $2.04L $1.68C $1.89VOL 771.7K

RES: $4.56SUP: $0.40SMA50: $1.64SMA200: $2.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TCRT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TCRT Butterfly Map → + Track TCRT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -50.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TCRT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TCRT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TCRT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TCRT)

Health Care Rank #936 of 1016 ⚔️ KPRX vs TCRT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TCRT vs. KPRX, MTVA, CURX, UPC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alaunos Therapeutics Inc. (TCRT) ranks #936 by composite RQD confidence (31/100, grade E) and #914 by equity capitalization ($7.8M). Within this direct 5-issuer industry benchmark cohort, TCRT leads on earnings valuation at N/A trailing P/E, while TCRT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MTVA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with TCRT at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TCRT ACTIVE Alaunos Therapeutics Inc.	E	31/100	—	—	-35.0%	-11.27%	$7.8M	Benchmark Subject
KPRX Kiora Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	-25.42%	$7.8M	/kprx-vs-tcrt →
MTVA MetaVia Inc.	D	47/100	—	—	-35.0%	+4.39%	$7.8M	/mtva-vs-tcrt →
CURX Curanex Pharmaceuticals Inc	D-	37/100	—	—	-35.0%	-0.20%	$7.7M	/curx-vs-tcrt →
UPC Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-20.21%	$7.7M	/upc-vs-tcrt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001107421

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alaunos Therapeutics Inc. (TCRT) reported GAAP revenue of $5.0K (-50.0% vs. FY2024 revenue of $10.0K , and 0.0% cumulative change since FY2023) , GAAP net income of -$4.2M, operating cash flow of -$2.9M, and free cash flow of -$3.0M (+40.3% YoY). On the balance sheet, TCRT closed FY2025 with $3.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.0K	-$4.2M	-$2.9M	-$3.0M	$3.0M	—
FY2024 (FY)	2024-12-31	$10.0K	-$4.7M	-$5.0M	-$5.0M	$2.8M	$0
FY2023 (FY)	2023-12-31	$5.0K	-$4.7M	-$30.1M	-$30.1M	—	—

3. TCRT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TCRT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alaunos Therapeutics Inc. (NASDAQ: TCRT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.89 (-11.27% 1D, market cap $7.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TCRT ranks #936 in composite RQD confidence.

How does TCRT compare to KPRX and MTVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TCRT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KPRX (Kiora Pharmaceuticals Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M) and MTVA (MetaVia Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, TCRT leads on earnings multiple (N/A) while TCRT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TCRT?

Per TCRT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001107421), Alaunos Therapeutics Inc. generated $5.0K in revenue (-50.0% YoY), -$4.2M in net income, and -$3.0M in free cash flow against $3.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TCRT trading relative to its 50-day, 200-day, and 52-week technical levels?

TCRT last traded at $1.89 (-11.27% on volume of 473,459 shares), positioning the stock +15.24% above its 50-day simple moving average ($1.64) and -18.88% below its 200-day simple moving average ($2.33). Across its 52-week range of $0.72 to $4.50, TCRT sits at the 31.0% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).

TCRT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are TCRT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TCRT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: TCRT RQD Cockpit TCRT 12M Forecast TCRT Earnings & Move TCRT Dividends & DRIP TCRT Insiders & 13F TCRT Whale Options TCRT Profit Sankey TCRT News & Why